retatrutide type 2 diabetes trial results Lilly's triple agonist delivers up to 71.2 lbs of weight loss Looking forward to when #retatrutide's

Gut Health: GLP-1 therapy can impact gut health

GLP-3 is not an established receptor name in mainstream endocrine literature

Administration of GLP-1 Most GLP-1 therapies are injected subcutaneously, under the skin

If retatrutide is licensed by the MHRA in the future, Second Nature plans to assess it as an option alongside our existing Wegovy and Mounjaro programmes

These include increasing redness that spreads beyond the injection site, warmth and tenderness that worsens rather than improves over 24-48 hours, pus or drainage from the injection site, red streaks extending from the site, and fever or chills following injection

Another difference is that most injectable GLP-1 medications for weight loss are administered once a week